Audio Conference: COVID-19’s Impact on Lab Industry Testing Volumes and Dynamics – January 2021 Update

UBS invites you to listen to the 1 hour audio conference recording, “COVID-19’s Impact on Lab Industry Testing Volumes and Dynamics – January 2021 Update,” to hear UBS Research Analysts and XiFin Executives discuss the latest impacts in the short and long term, that COVID-19 has had on the laboratory and diagnostic testing industry.

Key Takeaways:

• Learn how Laboratory and Diagnostic Testing Volumes have trended through the end of the year into early 2021 amid the ongoing 3rd Wave as well as testing capacity/pipeline expectations from a company that processes over $40bn of gross diagnostic claims annually
• Learn how the COVID-19 outbreak has impacted diagnostic volumes, mix, and reimbursement for a variety of diagnostic providers (hospital, regional, reference, and national providers)
• Understand the key factors that will impact COVID PCR and Serology testing volumes in 2021, including new platforms/instruments, direct to consumer tests coming on line, and expectations for PCR and Serology testing demand as the COVID Vaccine roll out continues
• Understand the financial conditions of the variety of diagnostic providers and how the COVID-19 outbreak might impact industry dynamics (National Labs, Hospital Labs, and Independent Labs) including Genetics/Infectious Disease Testing, M&A, and insourcing/outsourcing decision-making
• Insight into reimbursement dynamics for COVID PCR testing (Medicare, Medicaid, and Commercial) as well as industry efforts with regards to PAMA

UBS Speakers

• Kevin Caliendo, UBS Healthcare Supply Chain & HCIT Senior Analyst
• Dan Brennan, UBS Life Science Tools & Diagnostics Senior Analyst
• ​Matt Taylor, CFA, UBS US Medical Supplies & Devices
• Whit Mayo, UBS Healthcare Services and Managed Care Analyst

XiFin Featured Speakers

Lâle White
Executive Chairman & CEO

Kyle Fetter
Chief Operating Officer